Inflammation: The Innate Response to Tissue Damage

Inflammation is the local, protective response of vascularized tissue to injury, infection, or cell death, whose purpose (in the sense of evolved function, not intention) is to deliver plasma proteins and leukocytes to the site of damage, contain and destroy the inciting agent, and initiate repair. It is a core function of Physical and Chemical Barriers to Infection failing and the innate immune system responding — it does not require prior exposure to a pathogen and shows no immunological memory, distinguishing it from adaptive responses. Two physically distinct but co-regulated processes constitute acute inflammation. The vascular response consists of transient vasoconstriction (seconds), followed by vasodilation of arterioles that increases local blood flow (hyperemia), followed by increased permeability of postcapillary venules that lets plasma proteins and fluid escape into the tissue (exudate). The cellular response consists of the ordered recruitment of leukocytes — first neutrophils, then monocytes — from the vascular lumen, across the endothelium, and through the interstitium to the site of damage, driven by Cytokines and Chemokines: Signaling Molecules of Immunity gradients. Both processes are triggered and sustained by the same small family of chemical mediators: vasoactive amines (histamine, serotonin), lipid mediators (prostaglandins, leukotrienes), peptides (bradykinin), and cytokines (TNF-α, IL-1, IL-6, and chemokines such as IL-8/CXCL8). Acute inflammation is self-limited by design, typically resolving within days, and its outcome is one of: complete resolution (tissue returns to normal), scarring/fibrosis (if tissue damage was extensive or the tissue cannot regenerate), abscess formation (walled-off pus, mostly dead neutrophils and debris), or progression to chronic inflammation (weeks to years, dominated by macrophages and lymphocytes rather than neutrophils, often with tissue destruction and attempted repair occurring simultaneously).

Step 1 — Recognition and initial mediator release. Tissue injury or microbial invasion is sensed by resident sentinel cells — tissue macrophages and mast cells — via pattern-recognition receptors detecting pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) released from dying cells (ATP, uric acid, HMGB1, mitochondrial DNA). Mast cells degranulate within seconds, releasing pre-formed histamine. Activated macrophages secrete TNF-α and IL-1, cytokines that act on nearby endothelial cells within minutes to hours.

Step 2 — Vascular response. Histamine and, later, nitric oxide cause smooth muscle relaxation in arterioles: vasodilation increases blood flow to the area (this is rubor and calor — redness and heat, from more warm blood delivered to the surface). Simultaneously, histamine and bradykinin act on postcapillary venule endothelial cells, causing them to contract and pull apart at their intercellular junctions. This increased vascular permeability lets plasma — water, salts, and importantly proteins like fibrinogen and antibodies — leak into the interstitium as exudate, producing tissue swelling (tumor, edema). Slower blood flow through a widened, leakier vessel causes red cells to pack together in the center of the vessel (stasis), pushing leukocytes toward the vessel wall — a phenomenon called margination that sets up the next stage. Bradykinin and prostaglandin E₂ also directly sensitize nociceptive nerve endings, producing dolor (pain).

Step 3 — The leukocyte adhesion cascade. This is the mechanistic heart of inflammation and proceeds through five discrete, molecularly distinct steps at the postcapillary venule: 1. Rolling. Cytokine-activated endothelium rapidly displays P-selectin (released from pre-formed Weibel-Palade bodies within minutes) and later synthesizes E-selectin (peaking at 1–2 hours). These selectins bind sialyl-Lewis^x carbohydrate ligands (e.g., PSGL-1) on the neutrophil surface, forming weak, rapidly-breaking bonds that let the leukocyte roll along the endothelium rather than flow past it, slowing it from blood-flow speed to a crawl. 2. Activation. Chemokines (e.g., IL-8/CXCL8) displayed on the endothelial surface, bound to heparan sulfate proteoglycans, engage G-protein–coupled chemokine receptors on the rolling leukocyte. This triggers "inside-out" signaling that rapidly converts leukocyte integrins (LFA-1, Mac-1) from a low-affinity to a high-affinity conformation — a conformational change occurring in seconds. 3. Firm adhesion (arrest). High-affinity integrins now bind their endothelial ligands, ICAM-1 and ICAM-2 (upregulated by TNF-α and IL-1 over several hours), arresting the leukocyte's rolling completely — it stops and flattens against the vessel wall. 4. Transmigration (diapedesis). The adherent leukocyte extends pseudopods between adjacent endothelial cells, guided by PECAM-1 (CD31), expressed on both leukocyte and endothelial junctions and mediating homophilic binding that walks the cell through the junction, then through the venule's basement membrane (aided by secreted collagenases). 5. Chemotaxis. Once in the tissue, the leukocyte migrates directionally up a concentration gradient of chemoattractants — bacterial products (notably the formylated peptide fMLP), complement fragment C5a, leukotriene LTB4, and chemokines like CXCL8 — toward the site of maximal concentration, i.e., the injury or infection itself.

Step 4 — Sequence of cellular arrival and effector function. Neutrophils dominate the first 6–24 hours because they are far more abundant in blood and respond fastest to chemokine gradients; they phagocytose (see Phagocytosis: Mechanism and Killing) and kill microbes via oxidative burst and degranulation, then undergo apoptosis, often forming pus. Monocytes arrive later (24–48 hours), differentiate into macrophages in tissue, and both continue phagocytosis and begin secreting growth factors that initiate tissue repair — this handoff from neutrophil-dominated to macrophage-dominated infiltrate is a defining temporal feature of acute inflammation.

Step 5 — Resolution. Resolution is not passive dilution of mediators but an active, separately programmed process. Lipid mediators switch class from pro-inflammatory prostaglandins/leukotrienes to anti-inflammatory and pro-resolving lipoxins, resolvins, and protectins, which stop further neutrophil recruitment and promote macrophage-mediated clearance (efferocytosis) of apoptotic neutrophils. Anti-inflammatory cytokines (IL-10, TGF-β) dampen further activation. Lymphatic drainage removes excess fluid and debris. If the causative agent is eliminated and tissue architecture is intact, complete resolution occurs; if damage was extensive, fibroblasts lay down collagen, producing scar tissue instead.

Julius Cohnheim (1867) — direct visualization of the cascade. Before molecular biology existed, Cohnheim used the thin, transparent mesentery and tongue of live frogs under light microscopy to directly watch inflammation happen in real time. He observed that following irritation, blood flow in venules slowed dramatically (stasis), leukocytes progressively adhered to the vessel wall (what we now call margination and rolling), and — most strikingly — leukocytes were seen squeezing directly through the vessel wall into the surrounding tissue, disproving the older idea that white cells were simply formed in the tissue itself. This was the first direct proof that leukocytes actively emigrate from blood vessels to sites of injury, establishing the cellular half of the inflammatory response as a real, observable, ordered physical process rather than a hypothetical construct.

Elie Metchnikoff (1882) — inflammation as a defensive, purposeful process. Studying transparent starfish larvae, Metchnikoff inserted a rose thorn into a larva and the next day found motile cells surrounding the thorn, having migrated there and begun to engulf foreign material — the first direct demonstration that inflammation is a directed, cellular defense response, not merely tissue damage or a passive symptom of disease. This reframed inflammation from a purely pathological curiosity (something to be suppressed) into an adaptive host defense mechanism, work for which Metchnikoff shared the 1908 Nobel Prize.

Leukocyte adhesion deficiency (LAD) — the clinical proof that adhesion molecules are non-redundant. In the 1980s, clinicians described children with recurrent, severe bacterial infections, delayed wound healing, and — critically — an inability to form pus despite markedly elevated blood neutrophil counts (because neutrophils could not leave the vasculature). Molecular analysis (Anderson, Springer, and colleagues) traced LAD type 1 to mutations in the gene encoding the common β2 integrin subunit (CD18), which pairs with CD11a to form LFA-1 — the integrin responsible for firm adhesion to ICAM-1. Without functional integrin, neutrophils could roll but never arrest or transmigrate, directly confirming firm adhesion as an essential, non-bypassable checkpoint in the cascade. LAD type 2, a rarer defect in fucosylation of selectin ligands (sialyl-Lewis^x precursor), impairs the rolling step instead, producing a milder phenotype — the difference in disease severity between LAD-1 and LAD-2 patients experimentally confirmed that rolling and firm adhesion are mechanistically separable steps, each dispensable in a different partial way, exactly as the multistep model predicted.

Intravital microscopy in mouse cremaster muscle (modern era, e.g., work from the Ley and Butcher laboratories in the 1990s–2000s). Using genetically engineered mice lacking specific selectins, integrins, or chemokine receptors, combined with real-time video microscopy of leukocyte behavior in living venules, researchers could isolate each step of the cascade: P-selectin knockout mice show reduced rolling but not absent firm adhesion; blocking chemokine receptors abolishes the rolling-to-arrest transition without preventing rolling itself. This body of work confirmed, molecule by molecule, that the qualitative sequence first seen by Cohnheim under a simple microscope reflects a strict, genetically dissectible order of molecular handshakes.

Example 1 — Timing a wound infection from clinical presentation. A patient sustains a deep puncture wound at hour 0. At hour 6, a swab of the wound bed under the microscope shows an infiltrate that is 92% neutrophils, 6% monocytes, 2% lymphocytes. At hour 72, a repeat swab from a wound that has not been adequately debrided shows 35% neutrophils, 55% macrophages, 10% lymphocytes, with early fibroblast proliferation at the wound margins. Interpretation: the hour-6 sample is textbook acute inflammation — neutrophils dominate because they are the most abundant circulating leukocyte and respond fastest to IL-8/C5a/LTB4 gradients, arriving within 6–24 hours. The hour-72 sample reflects the expected handoff to monocyte-derived macrophages (arriving at 24–48 hours, now the dominant population) alongside the beginning of the repair phase (fibroblasts). If, instead, the hour-72 sample still showed 90% neutrophils with no macrophage transition and pus was re-accumulating, this would suggest a persistent, undrained source of bacterial stimulus (e.g., a retained foreign body) continually regenerating fresh neutrophil-attracting chemokines rather than a normal resolving wound — a clinically actionable distinction, prompting a search for a retained foreign body or abscess requiring drainage rather than antibiotics alone.

Example 2 — Predicting the consequence of a selective molecular block. Suppose an experimental anti-inflammatory drug selectively blocks E-selectin and P-selectin (but leaves ICAM-1, LFA-1, and chemokine receptors fully functional) at a site of induced skin injury in a mouse model. Reasoning through the cascade: selectins mediate rolling, the first, weak, transient-adhesion step that slows leukocytes from full blood-flow velocity to a crawl along the vessel wall. Without rolling, leukocytes never spend time in proximity to the endothelial surface long enough to sense surface-bound chemokines and undergo integrin activation — so even though LFA-1 and ICAM-1 are present and functional, they never get the chance to engage, because firm adhesion mechanistically depends on the prior rolling step. Prediction: neutrophil recruitment to the injury site should be sharply reduced (though not necessarily zero, since very high local chemokine concentrations can occasionally trigger integrin activation without formal rolling), and the animal should show a blunted, delayed inflammatory response with correspondingly slower bacterial clearance and delayed pus formation. This is precisely the phenotype seen in selectin-ligand-deficient (LAD-2-like) states — milder impairment than a full integrin block (LAD-1), because some residual capture can still occur via other selectin-independent, slow-flow mechanisms, illustrating why rolling is described as necessary-but-partially-redundant compared to the essentially non-bypassable integrin/ICAM-1 step.

Sir Thomas Lewis, a British cardiologist working in the early twentieth century, is a central but underappreciated figure in connecting the vascular events of inflammation to a testable chemical mechanism. Building on the ancient clinical description of the cardinal signs (attributed to the Roman writer Celsus in the first century CE: rubor, tumor, calor, dolor) and Cohnheim's direct microscopic observations of vessels, Lewis performed simple but decisive experiments on his own skin: stroking it firmly with a blunt instrument produced the "triple response" — a red line (local vasodilation), a surrounding flare (a wider zone of redness beyond the stroke itself), and a wheal (localized swelling). Lewis proposed that a diffusible chemical substance, released by the injured skin, was responsible for all three components, and he specifically implicated a histamine-like substance — work carried out well before histamine's role in inflammation was chemically confirmed by other investigators. His triple-response experiment became one of the standard teaching demonstrations of vascular inflammation and directly foreshadowed the later identification of histamine, released from mast cells and basophils, as a key first mediator of the vascular phase.

Understanding the inflammatory cascade underlies most modern anti-inflammatory drug design. Corticosteroids broadly suppress cytokine transcription and phospholipase A2 activity (blocking prostaglandin and leukotriene synthesis upstream). NSAIDs (aspirin, ibuprofen) inhibit cyclooxygenase enzymes, directly blocking prostaglandin synthesis and thereby reducing fever, pain, and vasodilation without touching the cellular recruitment machinery. Biologic therapies target specific cascade steps directly: anti-TNF-α antibodies (infliximab, adalimumab) treat rheumatoid arthritis and inflammatory bowel disease by blocking one of the earliest cytokine triggers; anti-integrin antibodies (natalizumab, vedolizumab) block leukocyte firm adhesion/transmigration in multiple sclerosis and Crohn's disease, directly exploiting the adhesion cascade mechanism described above. In sepsis and ARDS (acute respiratory distress syndrome), excessive, dysregulated systemic inflammation — not the pathogen itself — is often the proximate cause of organ failure, motivating research into pro-resolving lipid mediators (resolvins) as a therapeutic strategy to actively terminate inflammation rather than merely suppress it. In chronic disease, atherosclerosis is now understood substantially as a chronic inflammatory process in the arterial wall, with monocyte recruitment via the same adhesion-molecule cascade central to plaque formation — a discovery that reframed cardiovascular risk reduction around anti-inflammatory strategies (e.g., the CANTOS trial testing an anti-IL-1β antibody for cardiovascular event reduction). In agriculture and veterinary medicine, understanding mastitis and other livestock inflammatory diseases relies on the identical neutrophil recruitment framework. In wound care, chronic non-healing wounds (diabetic ulcers) are frequently understood as a failure of the normal neutrophil-to-macrophage transition and failure of resolution signaling, directly motivating topical and systemic pro-resolution therapeutics under active development.

Ask the tutor: How does the same adhesion-molecule cascade get hijacked or dysregulated in chronic diseases like atherosclerosis or rheumatoid arthritis?